{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:30:13Z","timestamp":1789065013407,"version":"build-2803163510"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Ricerca Fondamentale Orientata"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The aim of this study was to characterise clinical priority of adverse events with sacubitril\/valsartan for targeting preventive measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used the US Food and Drug Administration adverse event reporting system (worldwide pharmacovigilance database) to compare adverse events recording sacubitril\/valsartan as suspect with other cardiovascular drugs. Disproportionality analyses were performed by calculating the reporting odds ratios, deemed significant when the lower limit of the 95% confidence interval was greater than 1. Clinical priority was assigned to adverse events with significant disproportionality by scoring (range 0\u201310 points) five features (number of events, magnitude of the lower limit of the 95% confidence interval, mortality frequency, important\/designated medical event, biological plausibility).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sacubitril\/valsartan was recorded in 20,021 reports, with 178 adverse events associated with significant disproportionality: 71.9%, 25.9% and 2.2% were classified as weak, moderate and strong clinical priorities, respectively. Increased reporting emerged for several cardiovascular adverse events, including \u2018renal failure\u2019 (N\u2009=\u2009388; lower limit of the 95% confidence interval 2.26), \u2018hyperkalaemia\u2019 (314; 2.42) and \u2018angioedema\u2019 (309; 1.56). Sudden cardiac death (priority score 9 points) was the only designated medical event with strong clinical priority. Notably, sudden cardiac death occurred early after sacubitril\/valsartan administration (average onset 124 days), with concomitant drugs known for pro-arrhythmic potential (e.g. amiodarone, escitalopram, mirtazapine, loop diuretics) in 26.2% of records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The increased cardiovascular reporting of sacubitril\/valsartan in the real world was largely predictable from pre-approval evidence, underlying disease and likely patients\u2019 comorbidities. The unexpected reporting of sudden cardiac death occurred well before the complete development of positive electrical remodelling induced by sacubitril\/valsartan, and calls for stringent clinical monitoring (to reduce the pro-arrhythmic burden related to co-medications), and further investigation on appropriate combination with other preventive measures.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1177\/2047487320915663","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T03:27:16Z","timestamp":1587439636000},"page":"983-989","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":68,"title":["Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system"],"prefix":"10.1093","volume":"28","author":[{"given":"Milo","family":"Gatti","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippazio Cosimo","family":"Antonazzo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Diemberger","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"2021081715051287900_zwaa311-B1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ejhf.799","article-title":"Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides","volume":"19","author":"D\u2019Elia","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2021081715051287900_zwaa311-B2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2021081715051287900_zwaa311-B3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cardfail.2018.04.010","article-title":"Cognition- and dementia-related adverse effects with sacubitril-valsartan: analysis of the FDA Adverse Event Report System Database","volume":"24","author":"Perlman","year":"2018","journal-title":"J Cardiac Fail"},{"key":"2021081715051287900_zwaa311-B4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.687","article-title":"PARADIGM-HF Investigators and Committees. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction","volume":"19","author":"Cannon","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2021081715051287900_zwaa311-B5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.numecd.2016.02.006","article-title":"Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System","volume":"26","author":"Raschi","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2021081715051287900_zwaa311-B6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA Adverse Event Reporting System","volume":"14","author":"Raschi","year":"2019","journal-title":"Target Oncol"},{"key":"2021081715051287900_zwaa311-B7","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00228-018-2460-2","article-title":"Serious adverse drug reactions with sacubitril\/valsartan Entresto\u00ae: a French pharmacovigilance survey","volume":"74","author":"Moulis","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"2021081715051287900_zwaa311-B8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cardfail.2019.03.011","article-title":"Real-world prevalence of adverse events after initiating sacubitril\/valsartan compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure","volume":"25","author":"Adie","year":"2019","journal-title":"J Card Fail"},{"key":"2021081715051287900_zwaa311-B9","doi-asserted-by":"crossref","DOI":"10.3390\/diseases7020038","article-title":"A rare adverse event of rhabdomyolysis caused by sacubitril\/valsartan","volume":"7","author":"Rawla","year":"2019","journal-title":"Diseases"},{"key":"2021081715051287900_zwaa311-B10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s40800-016-0036-6","article-title":"Rhabdomyolysis after coadministration of atorvastatin and sacubitril\/valsartan (Entresto\u2122) in a 63-year-old woman","volume":"3","author":"Faber","year":"2016","journal-title":"Drug Safety Case Rep"},{"key":"2021081715051287900_zwaa311-B11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bcp.13545","article-title":"Three case reports of involuntary muscular movements as adverse reactions to sacubitril\/valsartan","volume":"84","author":"Bejan-Angoulvant","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2021081715051287900_zwaa311-B12","author":"Poluzzi","year":"2012"},{"key":"2021081715051287900_zwaa311-B13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40264-013-0075-1","article-title":"Choosing thresholds for statistical signal detection with the proportional reporting ratio","volume":"36","author":"Slattery","year":"2013","journal-title":"Drug Safety"},{"key":"2021081715051287900_zwaa311-B14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","article-title":"Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems","volume":"28","author":"Raschi","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2021081715051287900_zwaa311-B15","year":"2019"},{"key":"2021081715051287900_zwaa311-B16","year":"2016"},{"key":"2021081715051287900_zwaa311-B17","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021081715051287900_zwaa311-B18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2021081715051287900_zwaa311-B19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ejhf.1532","article-title":"Heart Failure Long-Term Registry Investigators. Sacubitril\/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency\/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world","volume":"21","author":"Kapelios","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021081715051287900_zwaa311-B20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1177\/2047487319835042","article-title":"CHECK-HF investigators. Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction","volume":"26","author":"Veenis","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2021081715051287900_zwaa311-B21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40264-017-0529-y","article-title":"Drug-induced arrhythmia: bridging the gap between pathophysiological knowledge and clinical practice","volume":"40","author":"Poluzzi","year":"2017","journal-title":"Drug Safety"},{"key":"2021081715051287900_zwaa311-B22","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"2021081715051287900_zwaa311-B23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","article-title":"Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices","volume":"15","author":"de Diego","year":"2018","journal-title":"Heart Rhythm"},{"key":"2021081715051287900_zwaa311-B24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/00015385.2018.1535818","article-title":"Switching from ramipril to sacubitril\/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction","volume":"75","author":"Okutucu","year":"2018","journal-title":"Acta Cardiol"},{"key":"2021081715051287900_zwaa311-B25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000496737","article-title":"Electrical storm after initiating sacubitril\/valsartan: arrhythmic paradox","volume":"142","author":"Okutucu","year":"2019","journal-title":"Cardiology"},{"key":"2021081715051287900_zwaa311-B26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000486410","article-title":"Ventricular arrhythmic storm after initiating sacubitril\/valsartan","volume":"139","author":"Vicent","year":"2018","journal-title":"Cardiology"},{"key":"2021081715051287900_zwaa311-B27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8101582","article-title":"Impact of sacubitril\/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients","volume":"8","author":"El-Battrawy","year":"2019","journal-title":"J Clin Med"},{"key":"2021081715051287900_zwaa311-B28","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2021081715051287900_zwaa311-B29","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2021081715051287900_zwaa311-B30","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibition in heart failure with mid-ranged ejection fraction: a systematic review and meta-analysis","author":"Memon","journal-title":"Eur J Prev Cardiol"},{"key":"2021081715051287900_zwaa311-B31","article-title":"Effects of sacubitril-valsartan, versus valsartan, in women compared to men with heart failure and preserved ejection fraction: insights from PARAGON-HF","author":"McMurray","year":"2019","journal-title":"Circulation"},{"key":"2021081715051287900_zwaa311-B32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2459\/JCM.0000000000000708","article-title":"Sacubitril\/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis","volume":"19","author":"Zac\u00e0","year":"2018","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2021081715051287900_zwaa311-B33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.hrthm.2017.11.029","article-title":"Do we still need ICDs if we have ARNi?","volume":"15","author":"Ehrlich","year":"2018","journal-title":"Heart Rhythm"},{"key":"2021081715051287900_zwaa311-B34","article-title":"Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis","author":"Perera","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2021081715051287900_zwaa311-B35","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1136\/heartjnl-2016-310794","article-title":"Heart failure in patients with kidney disease","volume":"103","author":"Tuegel","year":"2017","journal-title":"Heart"},{"key":"2021081715051287900_zwaa311-B36","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1177\/2047487318788394","article-title":"A step forward in resolving an old issue: treatment of heart failure with preserved ejection fraction and renal dysfunction?","volume":"25","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2021081715051287900_zwaa311-B37","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/2047487318780035","article-title":"Efficacy of renin\u2013angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease","volume":"25","author":"Tsujimoto","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2021081715051287900_zwaa311-B38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjd.15193","article-title":"Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum","volume":"177","author":"Wu","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2047487320915663","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2047487320915663","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/9\/983\/39768887\/zwaa311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/9\/983\/39768887\/zwaa311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T15:36:13Z","timestamp":1629214573000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/28\/9\/983\/6353458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,4,20]]},"published-print":{"date-parts":[[2021,8,9]]}},"URL":"https:\/\/doi.org\/10.1177\/2047487320915663","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2020,4,20]]}}}